Global Clinical Reach Imaging Endpoints operates as the largest global imaging CRO in oncology, with real-time scan processing from thousands of sites worldwide. This extensive international presence offers significant opportunities to expand partnerships with pharmaceutical companies seeking reliable global imaging solutions for multi-region clinical trials.

Proven Regulatory Excellence With a perfect inspection record and a 95% success rate in regulatory approvals across multiple agencies including the FDA and EMEA, Imaging Endpoints demonstrates a high quality standard. Partners and sponsors value reliable, compliant imaging data, making the company a preferred partner for regulatory-sensitive studies.

Innovative Scientific Leadership The company’s affiliation with world-class imaging scientists and high-profile publications positions it as a technology leader in medical imaging. This expertise attracts pharmaceutical clients investing in cutting-edge imaging tracers and diagnostics, opening avenues for collaborative R&D and early-phase clinical trials.

Expansion and Modernization Recent European office openings in Basel and the Netherlands, along with continued growth in Asia, indicate a strategic focus on expanding geographic reach. This provides opportunities to support local clinical trials and attract international clients seeking comprehensive global imaging services.

Strong Market Position With a revenue estimate between 50 and 100 million dollars and over 200 expert physicians on staff, Imaging Endpoints is well-positioned as a trusted provider in the competitive oncology imaging CRO space. This stability and reputation can be leveraged to target larger pharmaceutical firms and biotech companies seeking reliable, high-quality imaging collaborators.